

DCAT
TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*



1. [Pfizer To Invest \\$200 Million in Biologics Clinical Manufacturing Facility](#)

Pfizer has broken ground for a new \$200-million biologics clinical manufacturing facility in Andover, Massachusetts. The new building is expected to be operational by January 2019. [Read More](#)

2. [Mylan Closes on \\$1 Billion Acquisition of Topicals Business of Renaissance](#)

Mylan has completed the acquisition of the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings in deal valued up to \$1 billion. The acquisition provides Mylan with a complementary portfolio and pipeline of branded and generic topical products, an established US sales and marketing infrastructure targeting dermatologists, and an integrated manufacturing and development platform, including a topicals-focused CDMO, DPT Laboratories. [Read More](#)

3. [AstraZeneca Files Citizen's Petition To Defend Entry of a Generic Version of Crestor](#)

AstraZeneca has filed a Citizen Petition with the FDA requesting that the agency not approve any abbreviated new drug application or new drug application referencing the company's anti-cholesterol drug, Crestor (rosuvastatin calcium), until the expiration of the pediatric orphan drug exclusivity in 2023. The move is part of a generic defense strategy for Crestor, which was AstraZeneca's top-selling drug in 2015 with sales of \$5.02 billion. [Read More](#)

4. [The FDA To Rule on Amgen's Biosimilar for AbbVie's Humira in September](#)

A FDA advisory committee will review data supporting Amgen's biologics license application for ABP 501, a biosimilar candidate to AbbVie's Humira (adalimumab). The FDA has set a Biosimilar User Fee Act target action date of September 25, 2016 for ABP 501. Humira's was AbbVie's top-selling drug in 2015 with sales of \$14.012 billion. [Read More](#)

5. [German Supreme Court Grants Lilly Appeal in Alimta Patent Lawsuit](#)

The German Federal Supreme Court has granted an appeal by Eli Lilly and Company in its litigation with Actavis for Alimta (pemetrexed disodium). Alimta was Lilly's second highest selling drug in 2015 with sales of \$2.49 billion. [Read More](#)

6. [Sanofi Advances Strategy to Replace Medivation Board](#)

Sanofi has filed definitive consent solicitation materials with the US Securities and Exchange Commission seeking to remove and replace each member of Medivation's Board of Directors with eight independent candidates as Sanofi seeks to acquire Medivation in a \$9.4 billion takeover bid, a proposal that Medivation has thus far rejected and is advising its shareholders again to reject. [Read More](#)

7. [Famar To Acquire Roche's Facility in Leganes, Spain](#)

Famar, a CDMO, has agreed to acquire Roche's manufacturing site in Leganes, Spain and has signed a long-term supply agreement with Roche for products produced from the facility. This is the second acquisition of a manufacturing site for Famar this year. In May, it agreed to acquire a Canadian manufacturing facility from Bayer. [Read More](#)

8. [Hovione Breaks Ground on Expansion of NJ Facility](#)

Hovione has broken ground for the expansion of its facility in East Windsor, New Jersey. The expansion adds a new commercial spray dryer unit to complement the existing pilot unit, and this installation will be specifically designed to handle potent drug substances. In addition, the New Jersey facility will more than double its capacity to manufacture drug substances. [Read More](#)

9. [Dr. Reddy's To Acquire Eight Generics From Teva...](#)

Dr. Reddy's Laboratories has agreed to acquire eight abbreviated new drug applications from Teva Pharmaceutical Industries for \$350 million. The portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. [Read More](#)

10. [...And Sagent To Acquire Five ANDAs from Teva](#)

Sagent Pharmaceuticals has agreed to acquire a portfolio of five abbreviated new drug applications in the US from Teva Pharmaceutical Industries for \$40 million. The acquired portfolio includes products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. [Read More](#)

****Upcoming DCAT Event****

[DCAT Announces Its Newest Member Networking Event](#)

Enjoy all that Barcelona has to offer while making valuable industry connections at **DCAT After the Show**, DCAT's newest member networking event held immediately following CPhI Worldwide in Barcelona on Wednesday, October 5, from 6:00 PM to 8:30 PM. Located at the beautiful Casa Llotja de Mar, this venue is just steps away from the Gothic Quarter and Port of Barcelona, offering member company representatives the perfect opportunity to engage with colleagues they may have missed at the show before attending their customer events.

Registration for this event will open July 20, 2016. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599

www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org